Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05700448 | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 3 | 150 | CStone PharmaceuticalsINDUSTRY | 0 | May 27, 2026 | clinicaltrials |
| NCT07608549 | FLASH Pilot Phase 1 Safety Study | not yet recruiting | N/A | 10 | Lesley A. JarvisOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT07609355 |
| AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma(GLORIA) |
| not yet recruiting |
| N/A |
| 25 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| May 27, 2026 |
| clinicaltrials |
| NCT07609446 | Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | not yet recruiting | — | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | not yet recruiting | Phase 1 | 20 | GlaxoSmithKlineINDUSTRY | 0 | May 27, 2026 | clinicaltrials |
| NCT07602621 | Video-Assisted Emotional Preparation and Emotional Expression During Subcutaneous Procedures in Children With Cancer | not yet recruiting | N/A | 60 | Ege UniversityOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT07607327 | Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)(FORWARD) | not yet recruiting | — | 400 | CareDxINDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT07575893 | CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma(REACH-CD30) | not yet recruiting | Phase 1 | 12 | New York Medical CollegeOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07598110 | FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML(FT-RIC-HAPLO) | not yet recruiting | Phase 2 | 77 | Institut Paoli-CalmettesOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma(CONQUISTADOR) | not yet recruiting | Phase 1 / Phase 2 | 220 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07593482 | Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.(FC-BALANCE) | not yet recruiting | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia(E-STOP2) | not yet recruiting | Phase 4 | 136 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide(CUREMZL002) | not yet recruiting | Phase 2 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586709 | In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms | not yet recruiting | Early Phase 1 | 18 | Liping DouOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 50 | University of NebraskaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583303 | BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation | not yet recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584850 | Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Early Phase 1 | 9 | Ruijin HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 58 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07572175 | Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity(SPARTACUS) | not yet recruiting | Phase 2 | 60 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07572695 | Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | not yet recruiting | — | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT07573670 | A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia | not yet recruiting | Phase 2 | 52 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07468916 | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | not yet recruiting | Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567014 | Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS | not yet recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL(FRONTIER) | not yet recruiting | Phase 2 | 52 | Miltenyi Biomedicine GmbHINDUSTRY | 0 | May 6, 2026 | clinicaltrials |
| NCT07563543 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Early Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT07563920 | TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission(TBF-AML) | not yet recruiting | N/A | 93 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT05728879 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | not yet recruiting | Early Phase 1 | 30 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563023 | Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine | not yet recruiting | Early Phase 1 | 6 | West China HospitalOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07546630 | Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07552649 | Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia(MATCH-Treg) | not yet recruiting | Phase 2 | 28 | Antonio PieriniOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma(FLOURISH) | not yet recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07541326 | Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France(COMPLHEMATO) | not yet recruiting | N/A | 85 | University Hospital, LimogesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542418 | Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial | not yet recruiting | N/A | 204 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07538960 | Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica. | not yet recruiting | — | 350 | Caja Costarricense de Seguro SocialOTHER_GOV | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | not yet recruiting | Early Phase 1 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors | not yet recruiting | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539688 | Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07539779 | Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | not yet recruiting | Phase 2 / Phase 3 | 196 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | not yet recruiting | Phase 3 | 788 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535762 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | not yet recruiting | Phase 2 | 36 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07532746 | A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies | not yet recruiting | Phase 1 | 55 | Kousai Bio Co., Ltd.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06617286 | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 21 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2026source: clinicaltrials